Intellia Therapeutics (NASDAQ: NTLA) reported Q3 EPS of ($1.38), $0.12 better than the analyst estimate of ($1.50). Revenue for the quarter came in at $12 million versus the consensus estimate of $12.45 million.

For earnings history and earnings-related data on Intellia Therapeutics (NTLA) click here.